Retatrutide Half-Life: Why Once-Weekly Dosing Works
Published Lilly-authored research places retatrutide’s half-life at approximately 6 days. This page explains what that means for weekly dosing, accumulation, washout, and how to read the primary sources conservatively.
Update History ▾
Retatrutide (LY3437943) is Eli Lilly’s investigational GLP-1, GIP, and glucagon triple agonist. Search interest around retatrutide half-life is really a search for three related questions: how long the molecule stays in the body, why the trials dose it weekly, and how quickly exposure falls after the last dose. This page stays centered on those pharmacokinetic questions. For the regulatory answer, use the retatrutide approval tracker. For the week-by-week schedule, use the dosage guide.
Retatrutide’s published half-life is approximately 6 days. That figure comes from Lilly-authored literature and fits the way the compound has been studied across phase 1, phase 2, and phase 3: once-weekly dosing with gradual escalation. The practical implication is straightforward: retatrutide is a long-acting peptide that accumulates over the first several weeks and washes out gradually rather than disappearing after a day or two.
- The clearest published figure is approximately 6 days. Lilly’s 2023 gastric-emptying paper states that retatrutide has a half-life of approximately 6 days supporting once-weekly dosing.[1]
- Multiple primary sources support weekly dosing. Lilly’s 2022 Cell Metabolism paper and 2022 phase 1b Lancet trial both describe pharmacokinetics that support a once-weekly schedule.[2][3]
- The long half-life means overlap between doses. Weekly injections accumulate over the first several weeks before approaching a near-steady pattern. That is one reason escalation schedules are slow rather than abrupt.
- Washout is gradual, not immediate. If half-life is about 6 days, a simple 4-to-5-half-life estimate implies several weeks before most exposure clears. That is an inference from half-life math, not a direct washout trial readout.
- Half-life is not the same as duration of effect. Lilly’s early data showed body-weight effects persisting through day 43 after a single dose, showing that pharmacodynamic effects can extend beyond simple plasma-decay shorthand.[2]
- The safest wording is approximate, not over-precise. Some primary sources publish weekly-suitable PK without repeating a number, so the clean answer is that retatrutide behaves like a roughly 6-day, once-weekly peptide rather than a short-acting daily agent.
Retatrutide Pen 30mg. 300 clicks per pen, 99.262% HPLC purity, batch-linked verification from Dubai.
Order Research Pen →What Is the Half-Life of Retatrutide?
The most useful answer from the published Lilly literature is: retatrutide has a half-life of approximately 6 days. That wording appears in the 2023 Lilly-authored research letter on gastric emptying, which states that retatrutide has a half-life of approximately 6 days supporting once-weekly dosing.[1]
Earlier primary sources are directionally consistent even when they are less explicit. Lilly’s 2022 Cell Metabolism paper said the pharmacokinetic profile supported once-weekly dosing and that body-weight reduction persisted up to day 43 after a single dose.[2] Lilly’s 2022 phase 1b Lancet trial reported dose-proportional pharmacokinetics and again said the half-life supports once-weekly dosing.[3]
| Source | What it says | Why it matters |
|---|---|---|
| Cell Metabolism 2022 | PK supported once-weekly dosing; weight reduction persisted to day 43 after a single dose | Shows long action even in early clinical work |
| Lancet phase 1b, 2022 | Multiple weekly doses; dose-proportional PK; half-life supports weekly dosing | Confirms the weekly schedule in repeated human dosing |
| DOM research letter, 2023 | Half-life approximately 6 days supporting once-weekly dosing | Most direct open-access numeric figure |
| NEJM obesity phase 2, 2023 | Once-weekly dosing sustained over 48 weeks with escalation to higher maintenance doses | Shows the weekly model held through longer obesity studies |
| TRANSCEND-T2D-1, 2026 | Weekly phase 3 dosing with gradual 4-week step-ups to target dose | Late-stage design still matches long-acting PK logic |
Why Does a 6-Day Half-Life Matter?
A 6-day half-life means the molecule clears slowly enough that weekly dosing makes pharmacokinetic sense. Concentrations do not crash between injections. Instead, each weekly dose overlaps with residual exposure from the previous one, which creates the smoother long-acting profile Lilly used across its obesity and diabetes trials.
It also explains why the escalation schedules are conservative. Long-acting exposure accumulates over time, so higher maintenance doses are reached in steps rather than all at once. In Lilly’s 2026 phase 3 diabetes release, participants started at 2 mg once weekly and moved upward every 4 weeks until reaching the target maintenance arm.[5] The published obesity and diabetes programs use time as a tolerability tool.
How Long Does Retatrutide Stay in the System?
If retatrutide’s half-life is about 6 days, then clinically meaningful exposure can persist for several weeks after the last dose. A simple half-life estimate works like this: after one half-life about half the drug remains, after two half-lives about one-quarter remains, and after four to five half-lives only a small fraction is left. That puts rough washout in the 24-to-30-day range.
That timeline is an inference from half-life math, not a direct washout trial endpoint. Real biological effects do not switch off at one exact day. Appetite, gastric emptying, glycaemic effects, and weight trajectory can all fade on slightly different timelines.
| Half-lives elapsed | Approximate time | Approximate amount remaining |
|---|---|---|
| 1 | 6 days | 50% |
| 2 | 12 days | 25% |
| 3 | 18 days | 12.5% |
| 4 | 24 days | 6.25% |
| 5 | 30 days | 3.125% |
Does Retatrutide Build Up With Weekly Dosing?
Yes. A long half-life means each weekly dose arrives before the previous dose has fully cleared. Over the first several weeks, exposure accumulates until a near-steady pattern is reached. That accumulation is normal for long-acting peptides and is part of why the dose-escalation blocks in retatrutide trials are measured in weeks, not days.
In practical terms, this means the effect of a dose change is not fully visible the next morning. There is carry-over from previous weeks. That is why protocol design, tolerability monitoring, and escalation pacing matter more for retatrutide than they would for a short-acting daily compound.
Half-Life vs Duration of Effect
Half-life tells you how fast concentration declines. It does not tell you, by itself, exactly how long the biological effect lasts. Lilly’s 2022 Cell Metabolism paper reported that body-weight reduction persisted through day 43 after a single dose in early-phase work.[2] That does not mean the half-life is 43 days. It means the downstream pharmacodynamic effect outlasted the first week and remained measurable deep into the observation window.
The 2023 gastric-emptying paper adds another wrinkle: the authors noted that the time course of tachyphylaxis in gastric-emptying delay may be longer with retatrutide than with previously studied incretins.[1] Plasma exposure, appetite effects, and GI effects are related, but they are not interchangeable clocks.
What Does Half-Life Mean for Titration and Missed-Dose Logic?
Long half-life is one reason retatrutide protocols are written around weekly intervals and gradual step-ups. In the published phase 3 diabetes program, participants began at 2 mg once weekly and moved upward every 4 weeks until reaching the assigned maintenance arm.[5] The goal is not just efficacy. It is giving the body time to adapt while exposure accumulates.
The same principle applies to missed-dose interpretation: because concentrations decline gradually, retatrutide does not behave like a short-acting peptide that requires daily rescue logic. But the exact handling rule still depends on the specific published protocol. For exact weekly escalation paths and protocol-facing dose guidance, use the retatrutide dosage guide.
Is the Exact Half-Life Fully Settled in the Public Record?
Not perfectly. The most directly stated open-access figure is the approximately 6-day wording in Lilly’s 2023 DOM paper.[1] Other primary sources are less numeric and simply describe the pharmacokinetic profile as supporting once-weekly dosing.[2][3]
That is why the safest summary is conservative: retatrutide appears to be a roughly 6-day, once-weekly triple agonist. That wording is precise enough to be useful without pretending the public literature has given a more exact universal figure than it actually has.
Our Research Standards
This article cites peer-reviewed Lilly-authored pharmacokinetic papers, phase 1 and phase 2 trial publications, and late-stage program disclosures. Where the public record is approximate rather than exact, the copy says so directly. Read our editorial policy →
- Urva S, O’Farrell L, Du Y, et al. The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying. Diabetes Obes Metab. 2023. doi:10.1111/dom.15167
- Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9. doi:10.1016/j.cmet.2022.07.013
- Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400(10366):1869-1881. sciencedirect.com
- Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972
- Eli Lilly and Company. Lilly’s triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes. March 19, 2026. investor.lilly.com
- ClinicalTrials.gov. A Study of Retatrutide in Participants With Obesity. NCT04881760. clinicaltrials.gov
- ClinicalTrials.gov. TRANSCEND-T2D-1: A Study of Retatrutide in Participants With Type 2 Diabetes. NCT06354660. clinicaltrials.gov
Retatrutide Pen 30 mg
99.262% HPLC purity, Janoshik Analytical. 300 clicks per pen, batch-linked verification, ships from Dubai.
Order Retatrutide Pen →